Re-Engineered p53 Chimera with Enhanced Homo-Oligomerization That Maintains Tumor Suppressor Activity

[Image: see text] The use of the tumor suppressor p53 for gene therapy of cancer is limited by the dominant negative inactivating effect of mutant endogenous p53 in cancer cells. We have shown previously that swapping the tetramerization domain (TD) of p53 with the coiled-coil (CC) from Bcr allows f...

Descripción completa

Detalles Bibliográficos
Autores principales: Okal, Abood, Cornillie, Sean, Matissek, Stephan J., Matissek, Karina J., Cheatham, Thomas E., Lim, Carol S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114475/
https://www.ncbi.nlm.nih.gov/pubmed/24836513
http://dx.doi.org/10.1021/mp500202p

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114475/
https://www.ncbi.nlm.nih.gov/pubmed/24836513
http://dx.doi.org/10.1021/mp500202p

Ejemplares similares